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We have developed a robust, fully automated anti-parasitic drug-screening
method that selects compounds specifically targeting parasite enzymes and not
their host counterparts, thus allowing the early elimination of compounds with
potential side effects. Our yeast system permits multiple parasite targets to be
assayed in parallel owing to the strains’ expression of different fluorescent pro-
teins. A strain expressing the human target is included in the multiplexed
screen to exclude compounds that do not discriminate between host and parasite
enzymes. This form of assay has the advantages of using known targets and not
requiring the in vitro culture of parasites. We performed automated screens for
inhibitors of parasite dihydrofolate reductases, N-myristoyltransferases and
phosphoglycerate kinases, finding specific inhibitors of parasite targets. We
found that our ‘hits’ have significant structural similarities to compounds with
in vitro anti-parasitic activity, validating our screens and suggesting targets for
hits identified in parasite-based assays. Finally, we demonstrate a 60 per cent suc-
cess rate for our hit compounds in killing or severely inhibiting the growth of
Trypanosoma brucei, the causative agent of African sleeping sickness.2. Introduction
Parasitic diseases such as malaria, schistosomiasis, leishmaniasis, sleeping sick-
ness and Chagas disease affect millions of people every year, leading to severe
morbidity and death. For example, malaria caused by parasites of the genus
Plasmodium kills over half a million people every year [1]. The disease is pri-
marily treated by chloroquine, artemisinin and antifolates (e.g. pyrimethamine).
However, Plasmodium spp. have become resistant to all of these drugs [2].
There is a pressing need for new treatments targeting these diseases, which
have often been neglected because they overwhelmingly or exclusively affect
the inhabitants of developing countries [3,4]. However, this is changing with
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Foundation, Medicines for Malaria Venture, the Drugs for
Neglected Diseases initiative and the Institute for One
World Health [5,6], and companies such as Novartis [7],
GSK [8] and Pfizer. Various groups have developed
efficient high-throughput drug-screening methods based on
intact parasites [9–12]. These cell-based assays screen for
compounds that inhibit or kill pathogens cultured in vitro.
This provides assurance that the compound is active against
the pathogen, but provides no information about its mechan-
ism of action or general cytotoxicity. Moreover, for cell-based
assays, the pathogen must be culturable. This requirement is
particularly problematic when designing screens for anti-
parasitic compounds because it may be extremely difficult
or impossible to culture the parasite or one of its life cycle
stages outside of an animal host. For instance, Plasmodium
vivax (the major cause of malaria in South America and
southeast Asia) cannot be continuously maintained in vitro
[13], and techniques for cultivating liver stages of plasmodia
are still in their infancy, and do not generate sufficient
parasites for high-throughput automated screens [14].
Conversely, the biochemical strategy involves the selection
of a target protein whose activity is essential for the growth
or survival of the pathogen. This approach has the advantage
of selecting candidate compounds of known mechanism of
action; these can be rationally improved, particularly if the
target protein’s structure has been determined. The bio-
chemical strategy has the disadvantages that it provides
no information about drug uptake into cells, whether the
drug will kill the pathogen, or whether it will show general
cytotoxicity and thus be likely to injure the host [15].
To address these issues, we have designed an anti-
parasite assay based on genetically engineered yeast strains.
Our method enables automated, high-throughput, live-cell,
target-based screens to identify novel compounds that specifi-
cally inhibit the activity of proteins that have been suggested as
targets for anti-parasite drugs. This represents a complemen-
tary approach to parasite-based methods, and is able to
identify novel chemical scaffolds for further development as
anti-parasitic drugs.
The yeast Saccharomyces cerevisiae has been successfully used
as a host for the expression of heterologous proteins for over
three decades. Yeast cells expressing parasite proteins can pro-
vide a well-characterized and exploitable platform for screens
attempting to identify novel anti-parasitics. For example, dihy-
drofolate reductase (DHFR) is an anti-parasitic drug target that
is present in organisms ranging from bacteria to humans. It is
the target of pyrimethamine treatment of malaria and human
tumours, because rapidlygrowing cells require folate to produce
thymidine [16]. In yeast, dfr1 mutations lead to loss of DHFR
activity, and Sibley and co-workers [17–19] have achieved the
complementation of such mutations by overexpression of
human and Plasmodium DHFRs. They have also demonstrated
the suitability of the mutant strains for drug screens in plate
assays. Phosphoglycerate kinase (PGK) is a central enzyme in
glycolysis and gluconeogenesis, and is essential for the blood
stages of many parasites. However, the human enzyme is not
expressed in erythrocytes, and so PGK has been proposed as a
target for anti-parasitic drugs [20,21]. N-myristoyltransferase
(NMT) is an enzyme responsible for themodification of proteins
to enable their targeting tomembranes [22–24].NMTsare essen-
tial enzymes conserved from kinetoplastid parasites to humans
and are successful drug targets [23,24].We have engineered S. cerevisiae strains where genes
encoding enzymes that are essential for yeast growth
(DHFR, NMT or PGK) were deleted and their function com-
plemented by the heterologous expression of the orthologous
enzymes from either human or parasites. Yeast cultures,
which can be grown rapidly and at low cost, are ideal for
use in automated screens. Yeast cells are suitable hosts for
the expression of enzymes essential for different life stages
of parasites, some of which cannot be propagated in vitro,
thus providing a platform for in vivo drug screens. Yeast
cells can be refractory to drug treatments owing to a protec-
tive cell wall and the presence of multiple drug export
pumps. The most pleiotropic drug export pump in S. cerevi-
siae is Pdr5p; therefore, we engineered all of our strains to
lack this drug export protein and consequently sensitized
them to a large range of chemical entities.
Here, we report the construction of a series of strains that
are genetically identical apart from genes encoding different
heterologous drug targets, and fluorescent proteins that
allow the growth of multiple strains to be followed in a
single culture. By these means, the drug sensitivity observed
in a particular strain can be directly linked to the in vivo inhi-
bition of the heterologous target. This approach also allows
the early identification of compounds that exhibit general
cytotoxicity, and identifies compounds that inhibit the
activity of the target proteins from the parasites, but have
no effect on the equivalent human protein.
In this paper, the drug targets DHFR, PGK and NMT
from a range of human parasites are used as examples to
demonstrate the utility of our assay. We have identified com-
pounds that inhibit each of the target enzymes expressed in
yeasts, but fail to inhibit the corresponding human enzyme.
We performed Tanimoto chemical similarity searches between
our Plasmodium hits and compounds with demonstrated anti-
plasmodial activity in vitro [25–27], indirectly validating our
anti-plasmodial hit compounds and suggesting intracellular
targets for the compounds identified in parasite-based screens.
Moreover, we have screened a number of our ‘hit’ compounds
against Trypanosoma brucei grown in culture and shown that 60
per cent either kill or severely inhibit the growth of this parasite.3. Material and methods
3.1. Strain and plasmid constructs
Plasmids expressing heterologous targets were constructed by
cloning the coding regions for human or parasite DHFRs,
NMTs or PGKs downstream of the TetO2 of pCM188 (between
the BamHI and PstI sites), thus permitting regulatable
expression of the target (addition of 2–20 mg l21 of doxy-
cycline to the growth medium results in a progressively
lower expression from the promoter). The strain expressing
the drug-resistant P. vivax DHFR (PvRdhfr) was constructed
by mutating the following sites of the target enzyme: S58R,
S117N and I173L. The plasmid was transformed into a S. cere-
visiae yeast strain with a dfr1D/DFR1 pdr5D/PDR5 BY4743
background. The strain was sporulated and MATa haploids
were selected for drug screens (for description of all other
strains, see the electronic supplementary material, tables S1
and S2; see also [28]). Fluorescent plasmids were constructed
by replacing the coding region of yEmRFP from yEpGAP-
Cherry [29] with Venus, CFP or Sapphire [30], and replacing
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and maps, see the electronic supplementary material). Yeast
transformation and plasmid recovery were performed using
standard methods.
3.2. Growth conditions
Standard growth conditions comprised either YPD (2% pep-
tone, 1% yeast extract and 2% glucose) or YNB-glucose
(0.68% yeast nitrogen base without amino acids, 2%
ammonium sulphate and 2% glucose) with the relevant sup-
plements for all assays. Drug screens were performed with
yeast strains growing in YNB-glucose supplemented with
lysine. Yeast strains expressing heterologous DHFRs were
grown in the presence of 5 mg l21 of doxycycline.
3.3. Microscopy
Fluorescent cells were examined with an Olympus BX51
microscope using filters 41028 YGFP (Venus), 49001 ET CFP
(CFP), 31043 SAP/UV GFP (Sapphire) and 41043 HcRED1
(mCherry).
3.4. Competition experiments
Growth assays in YNB-glucose liquid media were performed
using a BMG Optima plate reader with the filters Venus (exci-
tation 500 nm/emission 540 nm), CFP (440 nm/490 nm),
Sapphire (405 nm/510 nm) and mCherry (580 nm/612 nm)
to allow a good discrimination between different fluoro-
phores. The initial gain was adjusted to 10 per cent and the
assays were run at 308C, with shaking, and measurements
taken every 15 min for a total of 30 h.
3.5. High-throughput screening, assay using laboratory
automation of mixed cultures
Pre-cultures were grown in selective medium (YNB-glucose
without leucine, histidine, uracil or methionine) to stationary
phase and 1 ml of each culture was inoculated into 100 ml of
the same medium. Pools of three strains, each labelled by the
expression of a different fluorescent protein, were incubated
at 308C, with shaking, for 4 h to ensure exponential growth.
Doxycycline (5 mg ml21) was then added to the culture to
reduce expression of the target enzyme. The culture was
attached to a Thermo Combi multidrop within the auto-
mation work cell. The culture was stirred throughout and
the room temperature maintained at 238C during assay
plate creation.
3.6. Automated assay plate creation
Fifty nanolitres of each chemical library compound (Maybridge
Hitfinder library of approximately 14 400 chemically diverse
compounds) were transferred to Matrix 384-well black clear-
bottom assay plates. Each well of the assay plates was then
inoculated with 50 ml of the pooled yeast culture (final com-
pound concentration of 10 mM). The assay plates then entered
a read-and-incubate cycle to determine the growth kinetics.
Fluorescence measurements were obtained using the high-
resolution BMG Polarstar plate reader, which allowed the
detection of fluorescence over a much larger dynamic rangethan that detectable using BMG Optima, hence avoiding
problems owing to detector saturation. Full details of these
automated procedures will be published elsewhere [31].3.7. High-throughput screening, quantification
of results
Fluorescence readings were stored in a relational database. To
allow comparison between the fluorescence readings taken
for different strains, we modelled the former as continuous
curves. In fitting a curve to the data, we followed a data-
oriented approach, whereby we approximate the curve
by cubic spline polynomials rather than assuming a particu-
lar curve function (e.g. exponential curve). From these growth
curves, biologically relevant parameters were extracted,
such as lagtime, mmax and maximum cell density (see the
electronic supplementary material; see also [32]).
Because yeast strains expressing parasite and human
targets bear different fluorophores, distinct growth curves
can be obtained for pooled strains within a microtitre well,
based on the fluorescence intensity at the given wavelength
versus time. As the heterologous yeast strains were labelled
with fluorescent proteins expressed from 2m plasmids
(which result in copy number variation between different
cells in the population), all assay plates contained a number
of control wells with the pool of yeast strains grown in the
absence of the test drugs, so that the fluorescence intensity
in each particular experiment could be internally controlled
for and normalized.
The strain minimum doubling time (inversely propor-
tional to the maximum growth rate) and biomass yield (net
change in fluorescence from the beginning to the end of the
assay) were calculated from each fitted growth curve. The
yield was divided by the minimum doubling time to give a
fitness score for the strain in the presence of the given drug.
Within each well, the fitness of the strains expressing either
parasite target (‘parasite’) was divided by the fitness score
of the strain expressing human target (‘human’) present in
the same well, to give a relative fitness indicating the speci-
ficity of the drug to the parasite target. Wells in which all
of the strains exhibited severely compromised growth were
removed from the analysis since they indicated either a tech-
nical problem with the well (e.g. autofluorescence of the
drug) or a drug toxic to yeast itself.
For each microtitre plate, average fitness scores were cal-
culated across the DMSO-only control wells. The s.d. of the
fitness scores of all of the non-control wells was calculated
for the plate. Where the ratio of the ‘parasite’-to-‘human’ fit-
ness scores was more than three plate standard deviations
smaller than the control-well value, the drug was deemed
to be a putative hit against the given parasite target. From
these candidates, if the ‘parasite’ fitness was less than 50
per cent of the ‘human’ fitness, the compound was added
to the list of hits.
Using these criteria, a list of hits was assembled for each of
the parasitic targets (see the electronic supplementarymaterial,
spreadsheet S1). The statistical significance of the overlap
between the hit lists for different targets was calculated by
applying the normal approximation to the hypergeometric
distribution, given the number of hits for each parasite target,
and the total number of hits and compounds screened (see
the electronic supplementary material, spreadsheet S2).
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We selected 36 Maybridge compounds classified as T. brucei
moderate/strong hits (growth of (strain expressing parasite
target)/(strain expressing the host target)  0.4) for vali-
dation using intact bloodstream form (BSF) parasites (Lister
427). A total of 1  105 BSF parasites were seeded into
24-well polystyrene plates in 1 ml HMI-9 supplemented
with 10 per cent foetal bovine serum, 100 U ml21 penicillin,
100 U ml21 streptomycin and 10 mM of test compounds (or
10 mM blasticidin as a positive control). Cultures were
grown in 5 per cent CO2 at 378C for 48 h, when scoring
the effect of the hit compounds on parasite growth was
performed by counting parasite concentrations using a hae-
mocytometer. Titration assays were then performed on
compounds that killed all parasites at 10 mM, at the following
concentrations: 10mM, 1mM, 100 nM, 10 nM and 1 nM. Some
1  106 BSF parasites (Lister 427) were seeded into 10 ml HMI-
9 (supplemented as above) and 1mM, 100 nMor 10 nMof com-
pound (as well as a no drug control) and were incubated in
25 cm2 non-adherent flasks with vented caps in 5 per cent
CO2 at 378C for 48 h. Proliferation was determined at 24 and
48 h by performing cell counts using a haemocytometer.
A similar assay was performed using T. brucei EATRO 1125
grown in HMI-9 supplemented with 10 per cent rabbit
serum, 100 U ml21 penicillin and 100 U ml21 streptomycin.
3.9. Validation of hits by structural similarity
Calls to Open Babel [33] calculated Tanimoto similarity
coefficients between pairs of SMILES strings, using the
‘Daylight-like’ hashed FP2 fingerprinting method, which were
then subtracted from 1 to give Tanimoto distance coefficients.
Pairwise comparison matrices of Tanimoto distance coefficients
were clustered hierarchically in R using the built-in ‘hclust’ func-
tion. Clustered pairwise comparison matrices were represented
as heatmaps using the ‘heatmap.plus’ function, which displays
colour-coded matrices alongside rows and columns.
Clustered pairwise comparison matrices were divided
into discrete clusters using R’s ‘cut’ function, which cuts den-
drograms at specific heights or into specified numbers of
clusters. For each cluster, the Small Molecule Subgraph
Detector Toolkit [34] passed the maximal common subgraph
(MCS) of each cluster to Open Babel, which wrote an .svg
image showing the structures of molecules in the cluster
with the MCS highlighted.
The three sets of Plasmodium falciparum whole-cell screen-
ing hits contained in the ChEMBL-NTD archive (https://
www.ebi.ac.uk/chemblntd, accessed 20/01/2012) were com-
bined, and duplicates deleted. Molecular structures, from
both the Maybridge Hitfinder library and the ChEMBL-NTD
archive, were retrieved and handled as SMILES (Simplified
molecular-input line-entry system) strings [35].4. Results
4.1. The fluorescent-yeast competition assay
We have constructed a compound-screening system that can
be multiplexed. A number of yeast strains, each expressing a
target protein for a different human parasite, can be grown in
competition in a single well of a microtitre tray, together witha strain expressing the equivalent human protein. This serves a
number of purposes. First, it increases the throughput of
the screen and allows compounds with the potential to treat
multiple diseases to be identified. Second, it enables the initial
selection of drug candidates to be made by identifying
compounds that significantly inhibit the growth of yeast cells
expressing the parasite target, without inhibiting the growth
of yeast expressing the equivalent human enzyme. Moreover,
any compound that exhibits general cytotoxicity is identified
by its inhibition of all the recombinant strains in the well,
irrespective of which target proteins they express. Finally, the
competition for nutrients between the different strains in
the well amplifies the growth rate differences between them.
Moreover, well-to-well variation in growth rate (an inherent
problem of microtitre-plate growth assays) is rendered
irrelevant because each well is internally controlled.
To these ends, we constructed a series of yeast multicopy
plasmids encoding a different fluorescent protein (mCherry,
CFP, Venus or Sapphire [29,30]) from the strong TDH3 pro-
moter and carrying different nutritional markers. Owing to
the high plasmid copy number and the TDH3 promoter,
expression of the fluorescent proteins was sufficient to
allow visualization of different colony colours by the naked
eye with or without UV illumination (figure 1a). The use of
plasmids to carry the genes for the fluorescent proteins
means that they can easily be swapped between strains
expressing the different target proteins in order to control
for any growth rate differences engendered by the expression
of the fluorescent proteins themselves. The data from internal
controls indicated that there were no problems with plasmid
stability or copy number. However, if such problems did
arise, integration of the genes for the fluorescent proteins
into a yeast chromosome would be an alternative.
In our pilot experiment, we engineered strains in which
the deletion of the essential yeast gene DFR1, which en-
codes DHFR, is complemented by the overexpression of
DHFR coding sequences (cds) from Homo sapiens (HsDHFR),
P. falciparum (PfDHFR), pyrimethamine-resistant P. falciparum
(PfRdhfr) and Schistosoma mansoni (SmDHFR) [28]. These cds
were each placed under the control of the TetO2 promoter
[36] such that they are downregulatable by the addition of
doxycycline to the culture medium. Each of these strains
was tagged with a different fluorescent protein (mCherry,
Sapphire, Venus and CFP, respectively) [29,30], enabling
them to be distinguished in a fluorescence assay for growth
(figure 1b). It should be noted that, in these pilot experiments,
fluorescence measurements were obtained using a BMG
Optima plate reader, which has a limited dynamic range.
For the high-throughput screens, we used a high-resolution
plate reader (BMG Polarstar); this has a much larger dynamic
range and avoids problems owing to detector saturation.
The sensitivity to the anti-malarial drug pyrimethamine of
strains expressing the wild-type P. falciparum DHFR and
Sapphire fluorescent protein was verified (figure 1c).
To evaluate the performance of the fluorescent-yeast com-
petition assay in a format suitable for high-throughput
screens, we tested the pyrimethamine sensitivity of pools of
three or four strains, each expressing a different fluorescent
protein. This demonstrated that effective discrimination
between the growth characteristics of the fluorescently labelled
strains growing in competition had been achieved (figure 2).
In addition, we determined whether the sensitivity of the
assay could be increased by reducing the expression of
UVBF
Venus
(a)
(b)
(c)
Sapphire
mCherry CFP
drug Bdrug Acontrol
PfRdhfr SmDHFR
PfDHFRHsDHFR
PfRdhfr SmDHFR
SmDHFR
PfDHFR
HsDHFR
drug C
no drug pyrimethamine
yHsDHFR + yEpmCherry
yPfDHFR + yEpSapphire
yPfRdhfr + yEpVenus
ySmDHFR + yEpCFP
SmDHFR
HfDHFR
Figure 1. Fluorescence labelling of yeast strains. (a) Wild-type yeast transformed with plasmids expressing Venus (yellow fluorescent protein), Sapphire (blue fluorescent
protein), mCherry (red fluorescent protein) or CFP (cyan fluorescent protein); visualized under bright field (BF) or ultraviolet (UV) light. (b) Schematic view of the exper-
imental design developed for high-throughput screens: yeast strains expressing heterologous drug-resistant Plasmodium falciparum DHFR (PfRdhfr), Schistosoma mansoni
DHFR (SmDHFR), human DHFR (HsDHFR) or P. falciparum DHFR (PfDHFR) growing in the presence of candidate anti-parasitic drugs. (c) Pictures of fluorescently labelled yeast
strains (expressing the indicated heterologous DHFRs) grown in competition in the presence or absence of the anti-malarial pyrimethamine.
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the TetO2 repressor, doxycycline. It was found that this treat-
ment increased the pyrimethamine sensitivity of the
yEpSapphire_ HIS/yPfDHFR strain by at least 50-fold (figure
2), which agrees with our previous results for plate assays [28].
4.2. High-throughput screening of a compound library
using laboratory automation
Using laboratory automation [37] we screened pools of three
strains (two expressing parasite targets and one expressing
the human orthologue) labelled with mCherry, Venus or
Sapphire. The screens were performed in the presence of
5 mg ml21 doxycycline and a library compound concentration
of 10 mM (chemically diverse Maybridge Hitfinder library).Following data acquisition for each of the fluorophores,
growth curves were generated (examples of growth curves
derived from fluorescence measurements from three wells
of one representative screen can be seen in figure 3) and
smoothed, and growth scores (minimum doubling time and
yield) were ascribed to each of the strains. Comparisons of
the growth scores for each compound–strain combination
allowed us to identify auto-fluorescent compounds or com-
pounds that target the fluorescent marker proteins and not
the parasite target. Problem wells, as well as compounds
that exhibit general cytotoxicity, were also recognized.
Finally, compounds that were active against the parasite
target, but had no significant effect on yeast expressing the
equivalent human protein, were designated as ‘hits’ (see the
electronic supplementary material, spreadsheet S1).
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Figure 2. Relative fluorescence measure detected using a BMG Optima plate reader at 580 nm (excitation)/612 nm (emission) (Cherry), 405 nm (excitation)/510 nm
(emission) (Sapphire), 500 nm (excitation)/540 nm (emission) (Venus) and 440 nm (excitation)/490 nm (emission) (CFP) of pooled yeast strains grown for 24 h in
the presence of 0 to 500 mM pyrimethamine and 0 or 5 mg ml21 of doxycycline. This plate reader has a limited dynamic range, and a higher-resolution instrument
was used for the high-throughput screens. Plasmodium falciparum DHFR (PfRdhfr) labelled with Venus, S. mansoni DHFR (SmDHFR) labelled with CFP, human DHFR
(HsDHFR) labelled with mCherry and P. falciparum DHFR (PfDHFR) labelled with Venus.
1000
10 000
100 000
400 20
time (h) time (h) time (h)
400 20 400 20
flo
ur
es
ce
nc
e 
(lo
g 1
0)
negative control (no drug) pyrimethamine (10 µM)
CI
NH2 NH2N
N
N N N
N
N
NN
CI
N S
test compound 9081(10 µM)
HsDHFR
PvDHFR
PfRDHFR
Figure 3. Example of a high-throughput screening result. Relative fluorescence measure detected using a BMG Polarstar plate reader at 580 nm (excitation)/612 nm
(emission) (Cherry), 405 nm (excitation)/ 510 nm (emission) (Sapphire) and 500 nm (excitation)/540 nm (emission) (Venus) of pooled yeast strains grown in the
presence of 5 mg ml21 of doxycycline AND 10 mM pyrimethamine, 10 mM of test compound or no drug. Plasmodium vivax DHFR labelled with Sapphire (blue
squares), human DHFR labelled with mCherry (red squares) and drug-resistant P. falciparum DHFR (PfRdhfr) labelled with Venus (yellow squares).
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the overlap between the hits defined in this way is highly
significant ( p 10214), demonstrating the reproducibility ofour screening method. In addition, instances of significant
overlap between the hits for the same molecular target in
different parasites reflect the relatedness of the two species
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Figure 4. Network of connections between kinetoplastid targets and our hits. Overview of the compounds from the Maybridge hitfinder library identified as specific
inhibitors of the following parasite (Trypanosoma brucei, Tb; T. cruzi, Tc; Leishmania major, Lm) targets: dihydrofolate reductase (DHFR), blue; N-myristoyltransferase
(NMT), red; phosphoglycerate kinase (PGK), green. Small nodes represent hits; yellow nodes represent compounds tested in T. brucei cultures. Diamond nodes represent
compounds active in Trypanosoma at 10 mM. Large diamonds represent compounds active in T. brucei cultures at 1 mM or less. The thickness of the edges (lines con-
necting the targets and compounds) represents the strength of the inhibition (thicker lines indicate stronger inhibition of growth of the yeast expressing the indicated
parasite target by the connecting compound).
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This reaffirms that our hit compounds are in fact specific for
some feature of the parasite target, conserved only between
closely related species. Plasmodium vivax and P. falciparum,
and Trypanosoma cruzi and T. brucei DHFRs share multiple
hits, as do WT and drug-resistant P. vivax and P. falciparum.
These latter compounds could represent promising leads in
addressing the drug-resistance problem.
4.3. Validation of confirmed hit compounds by
demonstrating their action against
Trypanosoma brucei in culture
We selected 36 hits against yeast strains encoding T. brucei,
T. cruzi or Leishmania major targets for validation usingintact T. brucei parasites. 18 of the tested compounds (50%)
were able to kill T. brucei Lister 427 bloodstream form para-
sites at 10 mM (after 48 h) and five additional compounds
were responsible for a severely reduced parasite yield
(figure 4 and table 1). The drugs capable of killing the
parasite at 10 mM were tested in titration experiments to
determine the minimum concentration necessary to kill
T. brucei Lister 427 parasites. All of the 10 mM hits were con-
firmed and seven of the compounds showed some effect at
1 mM, four were effective at 100 nM and two were effective
at 10 nM (table 1).
To better quantify our anti-trypanosomal compounds, we
followed the growth of T. brucei Lister 427 (a monomorphic
laboratory isolate) and EATRO 1125 (a pleomorphic isolate
with limited passage history) in the presence of 1 mM,
100 nM or 10 nM of 6 or 4 (respectively) different hit
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(1-methyl-2-[3-(1-methyl-1,2-dihydroquinolin-2-yliden)prop-
1-enyl]quinolinium iodide) and ID_14129 (2,4-dichloro-1-(2-
nitrovinyl)benzene) could kill virtually all parasites after
48 h at concentrations as low as 10 nM (table 1).
4.4. Chemoinformatic validation of hit compounds
We compared drug hits against different parasite targets (ident-
ified by screening the Maybridge Hitfinder library using our
fluorescence assay) with each other to identify structural fea-
tures associated with activity against a particular target. First,
molecular structures were represented as ‘fingerprints’ [38], bit-
strings encoding the structural features present in a molecule
and then the dissimilarities between pairs of fingerprints were
quantified as Tanimoto distance coefficients (TDC). Possible
TDC values range continuously from 0 (indicating identical fin-
gerprints) to 1 (indicating completely dissimilar fingerprints).
We constructed a pairwise Tanimoto distance matrix for our
‘hits’ using the Open Babel FP2 fingerprint.
We performed hierarchical clustering on this matrix to gen-
erate a ‘heatmap’ of the pairwise similarities between our hits
(see the electronic supplementary material, figure S1), with
hits for all parasites and targets on each axis. This showed sev-
eral clusters of similar structures. Additionally, there appeared
to be a correlation between these clusters and activity against
particular targets. For example, five compounds contained in
a tight cluster all showed activity against PfRdhfr exclusively
(see the electronic supplementary material, figure S1).
The dataset dendrogram was then ‘cut’ at different levels,
and the ‘MCS’ [39], or largest structural feature shared by
all members of a subset, was calculated for each cluster.
The size and complexity of this feature, as well as the sizes
and number of constituent compounds, provide a qualitative
insight as to the quality of clustering, as well as the significant
structural features.
At a cut level of 0.65 we obtained clusters that showed
clear distinguishing MCSs, such as for a cluster of hits show-
ing specificity against the PfDHFR and PfRdhfr targets (see
the electronic supplementary material, figure S2). The MCS
may represent the defining feature of a cluster, but there is
more information that can be obtained. For example, the clus-
ter of compounds displaying specificity for PfRdhfr alone
(see the electronic supplementary material, figure S2) has
an oxime ester as its MCS. From inspection of the structures,
it is apparent that subdivisions of the cluster would have
more complex common features. These are therefore features
that might work to increase the activity or specificity of a
compound, in tandem with the MCS.
Encouraged by the correlation between the structural
similarities of the hit compounds and their specific activity
against the parasite targets, we performed a similar TDC
analysis on the Plasmodium hits (P. falciparum: DHFR and
drug-resistant DHFR; P. vivax: DHFR and drug-resistant
DHFR, NMT and PGK) against the library of anti-plasmodial
compounds identified by GlaxoSmithKline, Novartis and
St Jude Children’s Hospital (www.ebi.ac.uk/chemblntd)
using screens against cultures of P. falciparum. We found
that 54 per cent of the compounds that our screen identified
as differentially active against P. falciparum had distance coef-
ficients of 0.5 or lower to at least one of the anti-plasmodial
compounds; and 29 per cent of the Plasmodium hits had
distance coefficients of 0.4 or lower (see figure 5a and
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Figure 5. Antiplasmodial hits. (a) Network of connections between drug targets and our Plasmodium hits. Overview of the compounds from the Maybridge hitfinder
library identified as specific inhibitors of the following parasite (P. falciparum, Pf, square nodes; P. vivax, Pv, large circular nodes) targets: dihydrofolate reductase
(DHFR), blue; drug-resistant dihydrofolate reductase (Rdhfr), light blue; N-myristoyltransferase (NMT), yellow; phosphoglycerate kinase (PGK), green. Small nodes
represents hits with Tanimoto distance coefficients of less than 0.4 (red), less than 0.5 ( pink) or greater than 0.5 (blue) to Chemblntd compounds identified in
P. falciparum in vitro screens (www.ebi.ac.uk/chemblntd). (b) Chemblntd compounds (compounds with demonstrated activity against P. falciparum in ex vivo assays)
and similar hits identified in our screens as potentially targeting PvPGK. Schematic depicting the structures of PvPGK-specific compounds identified in screens and
similar compounds with demonstrated activity against P. falciparum.
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arranged our anti-plasmodial hits based on their similarity
and plotted these compounds in a similarity heatmap againstthe Chemblntd compounds that had a TDC of 0.4 or lower to
our hits. In this manner, we could identify structural groups
with demonstrated in vitro anti-plasmodial activity, as well as
rsob.royalsocietypublishing.org
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compounds (see figure 5b and electronic supplementary
material, figure S3).
Our screens identified some compounds that were pleio-
tropic in their anti-parasitic target effects. For instance,
ID_3259 (N2-[3-(trifluoromethyl)phenyl]-5-nitro-2-furamide)
was effective against NMT, PGK and DHFR targets from
different parasite species (see figures 4 and 5, and electronic
supplementary material, spreadsheet S1). It is possible that
such ubiquitous activity represents some experimental
artefact. However, this concern was mitigated by the identifi-
cation of a large number of Chemblntd compounds with
TDC scores less than 0.5 to ID_3259 (see electronic sup-
plementary material, figure S5 and spreadsheet S3). Our
study may thus have defined a novel chemical scaffold on
which to base broad-spectrum anti-parasitic drugs. 01585. Discussion
We have developed a fully automated drug-screening
method based on engineering yeast to express parasite drug
targets or their human counterparts. The assay exploits the
fluorescent labelling of yeast cells to allow the growth of
three to four different strains in competition in the presence
of different library compounds. This approach provides
high sensitivity (owing to competition between strains), mini-
mizes plate-position effects and provides an internal control
for general cytoxicity. This approach is fast, cheap and
more flexible than drug screens against parasites in culture.
In this paper, we have reported the basis of our
fluorescent-yeast system and the results of a primary screen
carried out by using the Maybridge hitfinder library of
compounds. We chose to demonstrate the utility of using
the system to screen for drug candidates related to neglected
tropical diseases (NTDs) for two main reasons: their medical
and societal importance, and their tractability to drug discov-
ery. NTDs including schistosomiasis (caused by Schistosoma
spp.), leishmaniasis (Leishmania spp.), sleeping sickness
(T. brucei) and Chagas disease (T. cruzi) kill over half a million
people every year, a similar burden of disease to malaria
(Plasmodium spp.) [40]. These diseases affect the poorest
populations in Africa, Asia and Latin America. Conservative
estimates indicate an annual loss of 57 million disability-
adjusted life years owing to NTDs [40]. Collaborations between
not-for-profit organizations and for-profit companies are devel-
oping new drug-screening methods and identifying promising
new anti-parasitic compounds [41–44]. While these recent
advances are encouraging, the screens are generally limited to
a specific developmental stage of the target parasite.
A great strength of the system described in this work is that
it enables screens against targets from parasites at any of their
life-cycle stages, even if some or all of these are unculturable.
Thus, it combines most of the advantages of cell-based and
biochemical screens. Moreover, we have demonstrated its abil-
ity to identify compounds that can kill the target parasite by
testing a subset of our anti-kinetoplastid compounds in vitro
against T. brucei (which causes African sleeping sickness in
humans, and nagana in cattle) and observed that over 60 per
cent of our hits can successfully kill or severely inhibit
growth of the parasites (figure 4 and table 1). Having per-
formed T. brucei in vitro drug assays for 36 very diverse
compounds, with the aid of hierarchical clustering of ourhits (see the electronic supplementary material, figure S1),
we are now in a position to prioritize further compounds for
validation in parasites.
Some compounds that were highly active against T. cruzi
DHFR (e.g. ID_3951 (O1-[(5-nitro-2-furyl)carbonyl]-4-[2-nitro-
4-(trifluoromethyl)phenoxy]benzene-1-carbohydroximamide)
and ID_12803 (4-(tert-butyl)phenyl 5-nitrothiophene-2-car-
boxylate)) in the fluorescent-yeast system, but not selected
as ‘hits’ against T. brucei targets (probably due to our very
stringent selection threshold), nevertheless showed activity
against T. brucei in our in vitro assay (figure 4 and table 1).
This suggests that these compounds have the potential to
be used against multiple kinetoplastids. We also noticed
that compounds active against the Trypanosoma gPGK
(AAA32121.1) isoform screened in our system were poorly
validated in in vitro parasite-based assays, suggesting that
this enzymemight not be important for this particular parasite
life-cycle stage. However, this isozyme might still be essential
for a different stage of the parasite’s life cycle. Therefore, the
potential of our TbPGK hits as novel anti-parasitic agents
should not be dismissed before validation experiments using
alternative parasite life forms have been carried out.
Unlike the T. brucei PGK drug hits, the P. vivax PGK hits
had an excellent in silico validation rate, with all of the
PvPGK-only hits showing a TDC of 0.5 or less to compounds
validated in P. falciparum in vitro screens (see figure 5 and
electronic supplementary material, figure S3). This is not sur-
prising as Plasmodium genomes, like that of yeast, encode
only one PGK isoform. Hence, we provided good evidence
supporting Plasmodium PGK as a promising drug target,
and suggested a number of Chemblntd compounds for
target-based validation in the fluorescent-yeast system, as
well as in biochemical assays using recombinant P. falciparum
and P. vivax PGKs.
We have demonstrated the success of the fluorescent-
yeast method in identifying compounds that have high
specific activity against a range of drug targets from different
parasites (see the electronic supplementary material, spread-
sheet S1). In all cases, the system provided assurance that
the compound did not inhibit the biological activity of the
corresponding human enzyme. The compounds identified
as active against targets from parasites (in particular, against
those from P. vivax, for which we obtained the largest
number of hits) have great potential for use as scaffolds for
further chemical syntheses.
The approach described in this work is flexible enough to
be used in screens for drugs against many other parasites or
bacterial pathogens, or to screen for compounds specific to par-
ticular isoforms of human proteins [45].We have demonstrated
that this approach can work synergistically with current para-
site-based high-throughput screening methods. It can identify
chemical scaffolds for further development by the pharma-
ceutical industry [42], and also suggest the mechanism of
action of compounds identified in pathogen-based screens.
We believe that such synthetic biology screens based on classic
model organisms could provide a powerful newweapon in the
armoury of drug discovery and development.6. Acknowledgements
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